NCT00004030View on ClinicalTrials.gov

VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 31, 1996

Primary Completion Date

January 31, 2001

Study Completion Date

January 31, 2001

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

VX-853

DRUG

pegylated liposomal doxorubicin hydrochloride

Trial Locations (1)

20007

Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington D.C.

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Georgetown University

OTHER

NCT00004030 - VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin | Biotech Hunter | Biotech Hunter